The Chamber: ‘One More Bullet in J&J’s Gun’

In ‘For Plaintiffs Bar, Taking on J&J Means Battling a Shadow Foe,’ Law.com’s Amanda Bronstad reports on the “intimate relationship” between Johnson & Johnson (J&J) and the U.S. Chamber of Commerce (the Chamber). The U.S. Chamber of Commerce is not a government entity, but a powerful group of lobbyists, the largest in the nation. Plaintiff’s lawyers point out […]
In The New York Times: “Side Effects May Include Lawsuits”

One of the most-read articles in The New York Times regarding pharmaceutical drug product liability and whistleblower lawsuits quotes Stephen Sheller. Side Effects May Include Lawsuits BY DUFF WILSON NEW YORK – FOR decades, antipsychotic drugs were a niche product. Today, they’re the top-selling class of pharmaceuticals in America, generating annual revenue of about $14.6 billion […]